Concert Pharmaceuticals Inc. (CNCE) Rating Lowered to Sell at Zacks Investment Research
Concert Pharmaceuticals Inc. (NASDAQ:CNCE) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Tuesday.
According to Zacks, “Concert Pharmaceuticals Inc. is a biopharmaceutical company. It is focused on applying its DCE Platform (R) to create novel small molecule drugs. The Company manufactures drugs in various therapeutic areas such as hot flashes, HIV, renal hepatic, neuropathic pain, MRSA infection, and schizophrenia, multiple tumors, and hyperparathyroidism. Concert Pharmaceuticals Inc. is based in United States. “
A number of other research analysts also recently weighed in on the company. Stifel Nicolaus reissued a “buy” rating and issued a $23.00 price objective on shares of Concert Pharmaceuticals in a research note on Tuesday, September 27th. Brean Capital reissued a “buy” rating and issued a $25.00 price objective on shares of Concert Pharmaceuticals in a research note on Wednesday, September 7th. Two investment analysts have rated the stock with a sell rating and five have issued a buy rating to the stock. Concert Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $25.50.
Concert Pharmaceuticals (NASDAQ:CNCE) opened at 9.41 on Tuesday. Concert Pharmaceuticals has a 52 week low of $9.34 and a 52 week high of $25.04. The company’s 50-day moving average price is $10.06 and its 200 day moving average price is $11.76. The company’s market capitalization is $209.16 million.
Concert Pharmaceuticals (NASDAQ:CNCE) last announced its quarterly earnings results on Tuesday, August 9th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.63) by $0.03. Concert Pharmaceuticals had a negative return on equity of 29.09% and a negative net margin of 289.85%. On average, equities research analysts anticipate that Concert Pharmaceuticals will post ($2.51) EPS for the current year.
A number of hedge funds and other institutional investors have recently modified their holdings of CNCE. American International Group Inc. increased its position in shares of Concert Pharmaceuticals by 5.4% in the second quarter. American International Group Inc. now owns 9,490 shares of the company’s stock valued at $107,000 after buying an additional 483 shares in the last quarter. Rhumbline Advisers increased its position in shares of Concert Pharmaceuticals by 16.3% in the second quarter. Rhumbline Advisers now owns 17,248 shares of the company’s stock valued at $194,000 after buying an additional 2,414 shares in the last quarter. ProShare Advisors LLC increased its position in shares of Concert Pharmaceuticals by 1.8% in the second quarter. ProShare Advisors LLC now owns 18,558 shares of the company’s stock valued at $208,000 after buying an additional 326 shares in the last quarter. Algert Global LLC acquired a new position in shares of Concert Pharmaceuticals during the third quarter valued at approximately $202,000. Finally, Teachers Advisors Inc. increased its position in shares of Concert Pharmaceuticals by 10.6% in the second quarter. Teachers Advisors Inc. now owns 24,624 shares of the company’s stock valued at $277,000 after buying an additional 2,356 shares in the last quarter. 61.68% of the stock is currently owned by institutional investors.
Concert Pharmaceuticals Company Profile
Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others segment. It has clinical candidates under development, including AVP-786, CTP-656, CTP-730 and JZP-386.
Receive News & Stock Ratings for Concert Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.